Intracerebral metastases pathophysiology: Difference between revisions
Line 25: | Line 25: | ||
:Regulates remodeling of actin cytoskeleton during morphogenesis and motility<br> | :Regulates remodeling of actin cytoskeleton during morphogenesis and motility<br> | ||
:Important in tumor cell invasion<br> | :Important in tumor cell invasion<br> | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|1p21-p13 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 1|1p21-p13]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Lysyl oxidase|LOX]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Lysyl oxidase|LOX]]'' | ||
Line 33: | Line 33: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Increases invasiveness of hypoxic human cancer cells through cell matrix adhesion and focal adhesion kinase activity | :Increases invasiveness of hypoxic human cancer cells through cell matrix adhesion and focal adhesion kinase activity | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|5q23.1-q23.2 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 5|5q23.1-q23.2]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[VEGF]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[VEGF]]'' | ||
Line 44: | Line 44: | ||
:Angiogenic growth factor<br> | :Angiogenic growth factor<br> | ||
:Inhibition decreases brain metastasis formation; reduces blood vessel formation and cell proliferation; increases apoptosis<br> | :Inhibition decreases brain metastasis formation; reduces blood vessel formation and cell proliferation; increases apoptosis<br> | ||
|style="padding: 1px 1px; background: #F5F5F5;" align=center|6p21.1 | |style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 6|6p21.1]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Macrophage colony-stimulating factor|CSF1]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Macrophage colony-stimulating factor|CSF1]]'' | ||
Line 52: | Line 52: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Stimulate macrophage proliferation and subsequent release of growth factors | :Stimulate macrophage proliferation and subsequent release of growth factors | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|1p13.3 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 1|1p13.3]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[ID1]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[ID1]]'' | ||
Line 60: | Line 60: | ||
|style="padding: 1px 1px; background: #F5F5F5;" | | |style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Involved in matrix remodeling, intracellular signaling, and angiogenesis | :Involved in matrix remodeling, intracellular signaling, and angiogenesis | ||
|style="padding: 1px 1px; background: #F5F5F5;" align=center|20q11.21 | |style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 20|20q11.21]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Twist transcription factor|TWIST1]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Twist transcription factor|TWIST1]]'' | ||
Line 71: | Line 71: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Causes loss of E-cadherin-mediated cell-cell adhesion, activates mesenchymal markers, and induces cell motility by promoting epithelial-mesenchymal transition | :Causes loss of E-cadherin-mediated cell-cell adhesion, activates mesenchymal markers, and induces cell motility by promoting epithelial-mesenchymal transition | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|7p21.1 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 7|7p21.1]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[C-Met|MET]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[C-Met|MET]]'' | ||
Line 77: | Line 77: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Affects a wide range of biological activity depending on the cell target, varying from mitogenesis, morphogenesis, and motogenesis | :Affects a wide range of biological activity depending on the cell target, varying from mitogenesis, morphogenesis, and motogenesis | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|7q31.2 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 7|7q31.2]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" font-weight: bold" align=center |''[[MMP9|MMP-9]]'' | | style="padding: 3px 3px; background: #DCDCDC;" font-weight: bold" align=center |''[[MMP9|MMP-9]]'' | ||
Line 87: | Line 87: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Extracellular matrix degradation, tissue remodeling | :Extracellular matrix degradation, tissue remodeling | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|20q13.12 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 20|20q13.12]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[NEDD9]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[NEDD9]]'' | ||
Line 93: | Line 93: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Acquisition of a metastatic potential | :Acquisition of a metastatic potential | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|6p24.2 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 6|6p24.2]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Lymphoid enhancer-binding factor 1|LEF1]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[Lymphoid enhancer-binding factor 1|LEF1]]'' | ||
Line 100: | Line 100: | ||
:Transcriptional effecter—WNT pathway; predilection for brain metastasis<br> | :Transcriptional effecter—WNT pathway; predilection for brain metastasis<br> | ||
:Knockdown inhibits brain metastasis, decreases colony formation; in vitro decreases invasion<br> | :Knockdown inhibits brain metastasis, decreases colony formation; in vitro decreases invasion<br> | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|4q25 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 4|4q25]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[HOXB9]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[HOXB9]]'' | ||
Line 109: | Line 109: | ||
:Homeobox gene family; critical for embryonic segmentation and patterning. Also a TCF4 target<br> | :Homeobox gene family; critical for embryonic segmentation and patterning. Also a TCF4 target<br> | ||
:Knockdown in vitro decreased invasion and colony formation; in vivo appears to inhibit brain metastasis<br> | :Knockdown in vitro decreased invasion and colony formation; in vivo appears to inhibit brain metastasis<br> | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|17q21.32 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 17|17q21.32]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[BMP4]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[BMP4]]'' | ||
Line 117: | Line 117: | ||
| style="padding: 1px 1px; background: #F5F5F5;" | | | style="padding: 1px 1px; background: #F5F5F5;" | | ||
:Plays an essential role in embryonic development and may be an essential component of the epithelial-mesenchymal transition | :Plays an essential role in embryonic development and may be an essential component of the epithelial-mesenchymal transition | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|14q22.2 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 14|14q22.2]] | ||
|- | |- | ||
| style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[STAT3]]'' | | style="padding: 3px 3px; background: #DCDCDC;" align=center |''[[STAT3]]'' | ||
Line 124: | Line 124: | ||
:Cell signaling transcription factor<br> | :Cell signaling transcription factor<br> | ||
:Reduction suppresses brain metastasis; decreases angiogenesis in vivo and cellular invasion in vitro<br> | :Reduction suppresses brain metastasis; decreases angiogenesis in vivo and cellular invasion in vitro<br> | ||
| style="padding: 1px 1px; background: #F5F5F5;" align=center|17q21.2 | | style="padding: 1px 1px; background: #F5F5F5;" align=center|[[chromosome 17|17q21.2]] | ||
|} | |} | ||
Revision as of 22:44, 10 November 2015
Intracerebral metastases Microchapters |
Differentiating Intracerebral Metastases from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Intracerebral metastases pathophysiology On the Web |
American Roentgen Ray Society Images of Intracerebral metastases pathophysiology |
Risk calculators and risk factors for Intracerebral metastases pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Pathophysiology
Pathogenesis
Genetics
Genes involved in the pathogenesis of intracerebral metastases are tabulated below:[1]
Gene | Cancer site (primary) | Role and implications | Chromosome location |
---|---|---|---|
RHoC | Melanoma |
|
1p21-p13 |
LOX |
Breast |
|
5q23.1-q23.2 |
VEGF |
Lung |
|
6p21.1 |
CSF1 |
Breast |
|
1p13.3 |
ID1 |
Breast |
|
20q11.21 |
TWIST1 |
Breast |
|
7p21.1 |
MET | Renal cell cancer |
|
7q31.2 |
MMP-9 |
Colorectal |
|
20q13.12 |
NEDD9 | Melanoma |
|
6p24.2 |
LEF1 | Lung |
|
4q25 |
HOXB9 |
Lung |
|
17q21.32 |
BMP4 |
Lung |
|
14q22.2 |
STAT3 | Melanoma |
|
17q21.2 |
Gross Pathology
- Typically metastases are sharply demarcated from the surrounding parenchyme and usually there is a zone of peritumoral edema out of proportion with the tumor size.
- Common intracranial sites associated with subependymal giant cell astrocytoma include:[2]
- Cerebrum (80%)
- Cerebellum (15%)
- Brain stem (5% )
Gallery
-
This solitary brain metastasis from thyroid papillary carcinoma resulted in neurological symptoms. The thyroid primary was clinically occult. (Courtesy of Dr. Nikola Kostich, Minneapolis, MN.).[3]
Microscopic Pathology
The histopathological appearance of intracerebral metastases may vary with the type of primary tumor. Common findings are listed below:[4][5]
- Tubule formation/glands
- Well-circumscribed and sharply demarcated from surrounding tissue (with the exception of melanoma metastasis)
- Mitoses
- Nuclear atypia
- Nuclear hyperchromasia
- Variation of nuclear size
- Variation of nuclear shape
Gallery
-
Very low magnification micrograph demonstrating metastatic adenocarcinoma that from a colorectal primary, i.e. colorectal carcinoma, by immunostains on HPS stain. The cerebellum seen on the image has Bergmann gliosis and Purkinje cell loss.[6]
-
High magnification micrograph demonstrating metastatic adenocarcinoma that is from a colorectal primary, i.e. colorectal carcinoma, by immunostains on HPS stain. The cerebellum has Bergmann gliosis and Purkinje cell loss.[6]
-
High magnification micrograph of a brain metastasis on HPS stain demonstrating normal brain tissue on the left and tumor cells on the right. The sharp demarcation between tumor and normal is typical of brain metastases.[6]
-
Adenocarcinoma infiltrating the brain in a case of lung cancer on H&E stain.[6]
Immunohistochemistry
- The immunohistochemistry profile of intracerebral metastases may vary with the type of the primary tumor.[7]
- Intracerebral metastases are demonstrated by positivity to tumor markers such as:[7]
- General brain metastases: Pankeratin +ve, GFAP -ve
- Lung adenocarcinoma and small cell lung carcinoma: TTF-1 +ve, CK7 +ve, CK20 -ve
- Breast carcinoma: CK7 +ve, ER +ve, PR +ve, BRST2 +ve/-ve
- Colorectal carcinoma: CK20 +ve, CDX2 +ve, TTF-1 -ve, CK7 -ve
- Clear cell renal cell carcinoma: PAX8 +ve, vimentin +ve, CD10 +ve, CK7 -ve, CK20 -ve
- Melanoma: S-100 +ve, HMB-45 +ve, melan-A +ve.
Gallery
-
Immunohistochemistry profile of intracerebral metastases from an adenocarcinoma of lung (primary) demonstrating positivity to CK7, CK20, and TTF1.[8]
References
- ↑ Rahmathulla, Gazanfar; Toms, Steven A.; Weil, Robert J. (2012). "The Molecular Biology of Brain Metastasis". Journal of Oncology. 2012: 1–16. doi:10.1155/2012/723541. ISSN 1687-8450.
- ↑ Khuntia, Deepak (2015). "Contemporary Review of the Management of Brain Metastasis with Radiation". Advances in Neuroscience. 2015: 1–13. doi:10.1155/2015/372856. ISSN 2356-6787.
- ↑ Gross image of brain metastases. Libre pathology 2015. http://librepathology.org/wiki/index.php/Brain_metastasis. Accessed on November 10, 2015
- ↑ Microscopic features of brain metastasis. Libre pathology 2015. http://librepathology.org/wiki/index.php/Brain_metastasis. Accessed on November 10, 2015
- ↑ Microscopic appearance of brain metastases. Dr Bruno Di Muzio and Dr Trent Orton et al. Radiopaedia 2015. http://radiopaedia.org/articles/brain-metastases. Accessed on November 10, 2015
- ↑ 6.0 6.1 6.2 6.3 Microscopic images of brain metastasis. Libre pathology 2015. http://librepathology.org/wiki/index.php/Brain_metastasis. Accessed on November 10, 2015
- ↑ 7.0 7.1 IHC features of brain metastasis. Libre pathology 2015. http://librepathology.org/wiki/index.php/Brain_metastasis. Accessed on November 10, 2015
- ↑ IHC image of brain metastasis. Libre pathology 2015. http://librepathology.org/wiki/index.php/Brain_metastasis. Accessed on November 10, 2015